Clinical and Molecular Hepatology

Search

Close

Previous issues

Previous issues

Volume 27(2) Apr 2021
Print ISSN: 2287-2728
Online ISSN: 2287-285X

Reviews Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2021;27(2):221-235.
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.
Current and future strategies for the treatment of chronic hepatitis C
Omar Alshuwaykh, Paul Y. Kwo
Clin Mol Hepatol. 2021;27(2):246-256.
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.
Editorials A need for patient-centered care in managing patients with liver cirrhosis
Eileen L. Yoon
Clin Mol Hepatol. 2021;27(2):270-272.
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2021;27(2):273-277.
Biopsy or cytology for diagnosing hepatic focal lesions?
Haeryoung Kim
Clin Mol Hepatol. 2021;27(2):278-280.
Another oral antiviral treatment, but still far away from hepatitis B virus cure
Tai-Chung Tseng
Clin Mol Hepatol. 2021;27(2):281-282.
Original Articles Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study
Suk-Yong Jang, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Hyuk Soo Eun
Clin Mol Hepatol. 2021;27(2):283-294.
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clin Mol Hepatol. 2021;27(2):295-304.
Direct comparison of biopsy techniques for hepatic malignancies
Shang-Chin Huang, Ja-Der Liang, Shih-Jer Hsu, Tzu-Chan Hong, Hung-Chih Yang, Jia-Horng Kao
Clin Mol Hepatol. 2021;27(2):305-312.
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(2):313-328.
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding
Clin Mol Hepatol. 2021;27(2):329-345.
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol. 2021;27(2):346-359.
Letter to the Editor Clinical and serological prognostic markers in primary biliary cholangitis
Markus Wilhelmi
Clin Mol Hepatol. 2021;27(2):360-361.

Go to Top